Home / Library / Topic Index / HIV Continuum of Care / Step 5: Effective Drug Treatment of HIV

Step 5: Effective Drug Treatment of HIV

See also Antiretroviral Therapy, Adherence, and Initiating Treatment

Active Resources: 60

Online Training

Pocket Guides

Clinical Reference Tools

Webinars

Slide Sets

Toolkits

Image Library

Primary Care Guidelines

Charts, Tables & Posters

Antiretroviral Guidelines

Videos

Patient Information

Manuals

Articles & Bibliographies

Coinfection Guidelines (Hep, TB, STIs)

Fact Sheets

Articles: 10

  • Recap: 17th Ryan White HIV/AIDS Program Clinical Care Conference

    August 31, 2017

    Highlights from Laura W. Cheever, MD, ScM, HRSA HIV/AIDS Bureau Associate Administrator and Conference Co-Chair

    The field of HIV/AIDS care and treatment continues to evolve rapidly. Groundbreaking developments in HIV research are regularly presented at international meetings and...

  • CROI 2017: Failure of Dolutegravir Monotherapy

    April 17, 2017

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    Leading up to this year, some researchers and clinicians had optimistically viewed dolutegravir an invincible ARV, a drug so mighty that it was unlikely to fail, and even more unlikely to be victim to emergent resistance mutations. Two presentations at CROI demonstrated the...

  • Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy

    April 12, 2016

    Three studies presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) explored the pharmacokinetics of antiretrovirals administered during pregnancy. These studies support the use of standard-dose efavirenz, once-daily dolutegravir, and BID ritonavir-boosted...

  • Switching from TDF/FTC to TAF/FTC

    March 18, 2016

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    Researchers at the 2016 Conference on Retroviruses and Opportunistic Infections presented results from a randomized double-blind, double-dummy switch study of TAF/FTC. Over 660 patients with virologic suppression on TDF/FTC-containing 3-drug regimens were either switched to TAF/FTC (200/10 mg...

  • FDA Approves New TAF-Containing Analogue of Complera; Complera Approved for Pediatrics

    March 18, 2016

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    The FDA has approved a single-pill combination of rilpivirine + emtricitabine + tenofovir alafenamide (TAF); its brand name is Odefsey.

    It is intended for initial treatment of HIV-1-infected persons age 12 years and older whose pretreatment HIV RNA is ≤100,000 copies/mL, or as a substitute...

  • Rilpivirine Updates: Approved for Adolescents; Possible Risk of Depression

    October 1, 2015

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    The U.S. Food and Drug Administration has approved rilpivirine for use in adolescents 12 to 18 years of age; it is not recommended for younger children. As in adults, it is suggested for use in ARV-naive individuals with HIV RNA levels of ≤100,000 copies/mL. The dosage is 25 mg...

  • Pyrimethamine Availability

    October 1, 2015

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    Pyrimethamine is no longer available in retail pharmacies in the United States, though it is available through a commercial specialty pharmacy program (the application process, approval, and delivery of the medication will take at least 2 days; for information on ordering, click...

  • Adult and Adolescent Guidelines: Major Changes

    April 28, 2015

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    The U.S. Department of Health and Human Services has released new treatment guidelines for adults and adolescents, and these contain some important changes. Key among these is a major shakeup in the "Recommended Regimen Options" for initial therapy. 

    Efavirenz/TDF/FTC (Atripla) has...

  • Two New Boosted-PI Coformulations

    February 4, 2015

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    Two boosted protease inhibitor (PI) coformulations have just been approved by the FDA. These are:

    Darunavir 800 mg + cobicistat 150 mg (Prezcobix), andAtazanavir 300 mg + cobicistat 150 mg (Evotaz)

    In these fixed-dose combinations, cobicistat is used as the pharmacokinetic booster of the PI...

  • Efavirenz Updates: Bone Mineral Density & Suicidality

    August 1, 2014

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information
    Efavirenz and Bone Mineral Density

    Persons with HIV infection have a number of risk factors for decreased bone mineral density (BMD), related not just to effects of HIV or resulting illness but also to ART. For example, BMD decreases by as much as 5-6% after initiation of ART, and certain ARVs (...
Day Title
9/22
Southwest Alabama HIV Update (Alabama)
Friday, September 22, 2017 (All day) (Open Event)
Southeast AETC,
Alabama AIDS Education and Training Center
Event type: Conferences & Events
9/26
8th Annual ANAC Conference (Maryland)
Tuesday, September 26, 2017 - 8:30am EDT (Open Event)
MidAtlantic AETC
Event type: Conferences & Events
9/28
Hepatitis C Virus: Screening, Diagnosing and Treating in Primary Care (Georgia)
Thursday, September 28, 2017 - 12:00pm EDT (Open Event)
Southeast AETC,
Georgia AIDS Education and Training Center
Event type: Conferences & Events
9/29
The 13th Annual National Conference on HIV/AIDS & Aging (Massachusetts)
Friday, September 29, 2017 - 8:00am EDT (Open Event)
New England AETC
Event type: Conferences & Events
10/13
The Facts (Virginia)
Friday, October 13, 2017 - 8:30am EDT (Open Event)
MidAtlantic AETC
Event type: Conferences & Events
10/17
Institute of Human Virology (IHV) Case Conference (Maryland)
Tuesday, October 17, 2017 - 5:30pm EDT (Open Event)
MidAtlantic AETC
Event type: Conferences & Events
10/23
National Day of Action to End Violence Against Women with HIV (National)
Monday, October 23, 2017 (All day) (Open Event)
Event type: Awareness Days
Day Title
9/18
HIV Update: Daytona Beach Symposium (Florida)
Monday, September 18, 2017 (All day) (Open Event)
Southeast AETC
Event type: Conferences & Events
9/14
Advanced Management Issues in HIV Care (Ohio)
Thursday, September 14, 2017 - 6:00pm EDT to Friday, September 15, 2017 - 4:30am EDT (Open Event)
Midwest AETC
Event type: Conferences & Events
9/7
Contemporary Management of HIV (Mississippi)
Thursday, September 7, 2017 - 7:30pm EDT (Open Event)
Southeast AETC
Event type: Conferences & Events
6/5
HIV Long-Term Survivors Day (National)
Monday, June 5, 2017 (All day) (Open Event)
Event type: Awareness Days
6/4
International Association of Providers of AIDS Care (IAPAC) International Conference on HIV Treatment Adherence (Florida)
Sunday, June 4, 2017 (All day) to Tuesday, June 6, 2017 (All day) (Open Event)
Event type: Conferences & Events
5/22
2017 National Latino HIV and Hepatitis C Conference (National, Texas)
Monday, May 22, 2017 (All day) to Wednesday, May 24, 2017 (All day) (Open Event)
Valley AIDS Council,
South Central AETC
Event type: Conferences & Events
3/24
American Pharmacists Association Annual Meeting and Exposition 2017 (California)
Friday, March 24, 2017 (All day) to Monday, March 27, 2017 (All day) (Open Event)
Event type: Conferences & Events
3/7
Pediatric HIV/AIDS Training Course (Tennessee)
Tuesday, March 7, 2017 (All day) to Wednesday, March 8, 2017 (All day) (Open Event)
Event type: Conferences & Events
2/13
CROI 2017: Seattle (Washington)
Monday, February 13, 2017 (All day) to Thursday, February 16, 2017 (All day) (Open Event)
International Antiviral Society-USA
Event type: Conferences & Events